Journal of Medicinal Chemistry · 2010 · 112 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyInflammatory SignalingLung Cancer PharmacotherapyAnticancer ActivityAnticancer ChemotherapyAnticancer Natural ProductsCancer Cell Proliferation InhibitionClonogenic Survival AssaysNf-κb SignalingNuclear Factor Kappa B InhibitionTherapeutic Growth Inhibition
A series of curcumin analogues including new 4-arylidene curcumin analogues (4-arylidene-1,7-bisarylhepta-1,6-diene-3,5-diones) were synthesized. Cell growth inhibition assays revealed that most 4-arylidene curcumin analogues can effectively decrease the growth of a panel of lung cancer cells at submicromolar and low micromolar concentrations. High content analysis technology coupled with biochemical studies showed that this new class of 4-arylidene curcumin analogues exhibits significantly improved NF-κB inhibition activity over the parent compound curcumin, at least in part by inhibiting IκB phosphorylation and degradation via IKK blockage; selected 4-arylidene curcumin analogues also reduced the tumorigenic potential of cancer cells in a clonogenic assay.
30
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Ann‐Lii Cheng, Chih‐Hung Hsu, Jen‐Kou Lin et al. · PubMed · 2001 · 2.1K citations
Medicine, Oncology, Pharmacology +10
Larry Rubinstein, Robert H. Shoemaker, Kenneth D. Paull et al. · JNCI Journal of the National Cancer Institute · 1990 · 931 citations
Medicine, Oncology, Pharmacology +14